List view / Grid view
28 July 2016 | By Epidarex Capital
Epidarex Capital announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome...
In the pre-imatinib (Glivec®) era, two out of three patients died within five years from chronic myeloid leukemia and there was no hope for a curative treatment. Imatinib’s introduction in 2001 marked a breakthrough – as the first approved kinase inhibitor, it was a game-changer in cancer therapy and revolutionised…
13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.
In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...
18 April 2016 | By Victoria White, Digital Content Producer
SEL24 is a dual inhibitor of PIM and FLT3 kinases. It is the first molecule with this mechanism of action to progress to such stage of development...
4 February 2016 | By Victoria White
The new site will be located at in the Wielkopolska Centre of Advanced Technologies, Poznan, and commence research activities in the summer of 2016...
3 November 2015 | By Victoria White
The aim of the collaboration is to deliver potential first-in-class small molecules as lead candidate drugs for multiple oncology indications...
22 September 2015 | By Victoria White
The companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets...
21 September 2015 | By Victoria White
Appreciating the importance of the US biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc...
5 May 2015 | By Victoria White
Selvita, a global drug discovery company with offices in the US and Poland, is opening its first office in the UK in Cambridge...
31 March 2015 | By Victoria White
Selvita announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate...
7 November 2014 | By Felicitex Therapeutics and Selvita
Felicitex Therapeutics and Selvita have announced that they have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors...
